2-chloro-4-(piperidin-1-yl)benzoic acid | 313674-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-chloro-4-(piperidin-1-yl)benzoic acid
• 英文别名: 2-Chloro-4-piperidinobenzenecarboxylic acid；2-chloro-4-piperidin-1-ylbenzoic acid
• CAS: 313674-11-2
• 化学式: C₁₂H₁₄ClNO₂
• mdl: MFCD09152730
• 分子量: 239.702
• InChiKey: PUEGNVWKMCMZTI-UHFFFAOYSA-N

物化性质

• 熔点：
  224-226°
• 沸点：
  423.1±35.0 °C(Predicted)
• 密度：
  1.287±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  2-chloro-4-(piperidin-1-yl)benzoic acid 在 N-甲基吡咯烷酮 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 2-Chloro-4-piperidin-1-yl-benzoyl chloride
  参考文献：
  名称：

  Novel Design of Nonpeptide AVP V₂ Receptor Agonists:  Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template

  摘要：

  The discovery of a series of nonpeptide arginine vasopressin V-2 receptor agonists is described. After identifying the aniline derivative 8 as our lead compound from the metabolites of compound 7 that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken. These studies led to compounds leg, 19a, and 23b,h,i that show patent; agonist activity for the V-2 receptor.

  DOI：

  10.1021/jm000108p
• 作为产物：
  描述：

  2-氯-4-氟苯甲酸甲酯 在 sodium hydroxide 、 potassium carbonate 作用下， 以 N-甲基吡咯烷酮 、 甲醇 为溶剂， 反应 20.0h， 生成 2-chloro-4-(piperidin-1-yl)benzoic acid
  参考文献：
  名称：

  Novel Design of Nonpeptide AVP V₂ Receptor Agonists:  Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template

  摘要：

  The discovery of a series of nonpeptide arginine vasopressin V-2 receptor agonists is described. After identifying the aniline derivative 8 as our lead compound from the metabolites of compound 7 that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken. These studies led to compounds leg, 19a, and 23b,h,i that show patent; agonist activity for the V-2 receptor.

  DOI：

  10.1021/jm000108p

文献信息

• THIAZEPINE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2119719A1

  公开（公告）日：2009-11-18

  The present invention relates to a thiazepine derivative or a pharmacologically acceptable salt thereof having an excellent effect of inhibiting 11β-hydroxysteroid dehydrogenase type 1. A thiazepine derivative or a pharmacologically acceptable salt thereof having general formula (I): wherein R1 represents a hydrogen atom, a C1-C6 alkyl group or the like; R2 represents a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 hydroxyalkyl group, or the like; R3 represents a hydrogen atom or a C1-C6 alkyl group; R4 represents a C6-C10 aryl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group a or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group a; Substituent Group a consists of a halogen atom, a C1-C6 alkyl group, a C6-C10 aryl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group b, and so forth; Substituent Group b consists of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, and so forth.

  本发明涉及一种噻吩啶衍生物或其药理学上可接受的盐，具有优异的抑制11β-羟基类固醇脱氢酶1型的作用。具有通式（I）的噻吩啶衍生物或其药理学上可接受的盐： 其中 R1代表氢原子、C1-C6烷基或类似物；R2代表C1-C6烷基、C1-C6卤代烷基、C1-C6羟基烷基或类似物；R3代表氢原子或C1-C6烷基；R4代表可能被1至5个独立选择自取代基团a的基团取代的C6-C10芳基，或可能被1至3个独立选择自取代基团a的基团取代的杂环基团；取代基团a由卤原子、C1-C6烷基、可能被1至5个独立选择自取代基团b的基团取代的C6-C10芳基等组成；取代基团b由卤原子、C1-C6烷基、C1-C6卤代烷基等组成。
• Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V2 receptor agonists
  作者：Issei Tsukamoto、Hiroyuki Koshio、Seijiro Akamatsu、Takahiro Kuramochi、Chikashi Saitoh、Takeyuki Yatsu、Hiroko Yanai-Inamura、Chika Kitada、Eisaku Yamamoto、Shuichi Sakamoto、Shin-ichi Tsukamoto

  DOI：10.1016/j.bmc.2008.09.039

  日期：2008.11

  The present work describes the discovery of novel series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin (AVP) V(2) receptor agonists. By replacing the amide juncture in YM-35278 with a direct ring connection gave compound 10a, which acts as a V(2) receptor agonist. These studies provided the potent, orally active non-peptidic V(2) receptor

  本工作描述了作为精氨酸加压素（AVP）V（2）受体的新系列（4,4-二氟-1,2,3,4-四氢-5H-1-苯并ze庚因-5-亚基）乙酰胺衍生物的发现。激动剂。通过用直接环连接取代YM-35278中的酰胺键，得到化合物10a，它起V（2）受体激动剂的作用。这些研究提供了有效的，口服活性的非肽V（2）受体激动剂10a和10j。
• Diacylglycerol Acyltransferase Inhibitors
  申请人：Bolin David Robert

  公开号：US20100113782A1

  公开（公告）日：2010-05-06

  Provided herein are compounds of the formula (I): were R1 is phenyl, R2 is hydrogen, halogen or lower alkyl, X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a 4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of triglicerides such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了化合物的公式（I）：其中R1为苯基，R2为氢、卤素或低碳烷基，X为碳或氮，R3为异喹啉基、氨基或含有4至6个成员的杂环烷基环，并且其药学上可接受的盐，这些化合物作为DGAT抑制剂具有活性，因此可用于治疗与三酸甘油酯异常代谢相关的疾病，例如肥胖症、2型糖尿病和代谢综合征。
• BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS
  申请人：AKAMA Tsutomu

  公开号：US20150361104A1

  公开（公告）日：2015-12-17

  This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

  该发明提供了一些新的化合物，可以用于治疗原虫感染，其中还包括含有这些化合物的制药组合物，以及这些化合物与至少一种其他治疗有效的药物的组合。
• [EN] BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS<br/>[FR] MOLÉCULES DE PETITE TAILLE CONTENANT DU BORE EN QUALITÉ D'AGENTS ANTI-PROTOZOAIRES
  申请人：ANACOR PHARMACEUTICALS INC

  公开号：WO2014121124A1

  公开（公告）日：2014-08-07

  This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

  这项发明提供了一些新化合物，可用于治疗原虫感染，包括含有这些化合物的制药组合物，以及这些化合物与至少一种其他治疗有效剂的组合。